A Phase II, double-blind, placebo-controlled, randomized study to assess the efficacy, safety and tolerability of Lymfactin (AdAptVEGF-C Adenoviral Vector) in combination with a surgical lymph node transfer for the treatment of patients with secondary lymphedema associated with the treatment of breast cancer
Latest Information Update: 17 Feb 2025
At a glance
- Drugs AdVEGF-Herantis (Primary)
- Indications Lymphoedema
- Focus Therapeutic Use
- Acronyms AdeLE
- Sponsors Herantis Pharma
Most Recent Events
- 01 Feb 2025 Results published in the Plastic and Reconstructive Surgery
- 18 Oct 2023 Planned End Date changed from 7 Mar 2022 to 31 Dec 2024.
- 01 Nov 2022 Results published in the Journal of Plastic, Reconstructive and Aesthetic Surgery: JPRAS